MannKind Advances Nintedanib DPI Program with Phase 1b Completion and Phase 2 Trial Initiation
Event summary
- MannKind completed patient randomization in the Phase 1b INFLO-1 study for nintedanib DPI in IPF patients.
- First patient enrolled in the global Phase 2 INFLO-2 trial, expected to enroll 210 participants across 85 sites.
- Phase 1b data readout anticipated in Q3 2026, assessing safety, tolerability, and pharmacokinetics.
- Nintedanib DPI leverages Technosphere® technology to deliver therapy directly to the lungs, aiming to reduce systemic side effects.
The big picture
MannKind's advancement into mid-stage clinical evaluation for nintedanib DPI marks a critical inflection point in the development of therapies for idiopathic pulmonary fibrosis (IPF). The company aims to leverage its Technosphere® technology to deliver nintedanib directly to the lungs, potentially improving tolerability and adherence compared to existing oral therapies. With an estimated 100,000 IPF patients in the U.S. and a global prevalence of 1-1.5 million, the success of this program could significantly impact the treatment landscape for a disease with substantial unmet medical needs.
What we're watching
- Clinical Validation
- How the Phase 1b data in Q3 2026 will validate the safety and tolerability of nintedanib DPI.
- Execution Risk
- Whether MannKind can sustain momentum in patient enrollment and data readouts.
- Market Differentiation
- The pace at which nintedanib DPI can differentiate itself in the IPF market.
Related topics